Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients (ROCO2)
Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Chronic hepatitis C : Detectable HCV RNA, Previously treated with interferon or interferon combined with ribavirin, Elevated ALT level
- HIV infection (CD4>250/µL, HIV RNA<10 000 copies/ml) treated or not with antiretroviral therapy
- Signed informed consent
Exclusion Criteria:
- Chronic hepatitis B
- Alcohol consumption>40g/day
- Evidence of decompensated liver disease
- Hepatocellular carcinoma
- Other relevant disorders: organ transplantation, psychiatric or cardiovascular disease, poorly controlled diabetes, seizure disorders, hemoglobinopathy, autoimmune disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients with a sustained virological response, defined as an undetectable HCV RNA level
Time Frame: 24 weeks after the end of anti-HCV treatment
|
24 weeks after the end of anti-HCV treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety of treatment
|
|
|
Proportion of patients with a virological response
Time Frame: at weeks 24 and 48
|
at weeks 24 and 48
|
|
Influence of anti-HCV treatment on CD4 count and HIV RNA
|
|
|
Proportion of patients with histological response 24 weeks after the end of anti-HCV treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Geneviève CHENE, Pr, University Hospital, Bordeaux
- Principal Investigator: Didier Neau, MD-PhD, Hôpital Pellegrin, 33076 Bordeaux Cedex, France
Publications and helpful links
General Publications
- Thiebaut R, Guedj J, Jacqmin-Gadda H, Chene G, Trimoulet P, Neau D, Commenges D. Estimation of dynamical model parameters taking into account undetectable marker values. BMC Med Res Methodol. 2006 Aug 1;6:38. doi: 10.1186/1471-2288-6-38.
- Seydi M, Morlat P, Bonnet F, Rambeloarisoa J, Bernard N, Lacoste D, Bonarek M, Trimoulet P, Ramanampamonjy R, Lafon ME, Drame M, Beylot J. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up]. Rev Med Interne. 2005 Apr;26(4):280-7. doi: 10.1016/j.revmed.2004.11.022. French.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Digestive System Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Flaviviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Pathological Conditions, Signs and Symptoms
- HIV Infections
- Hepatitis C
- Hepatitis C, Chronic
- Nucleic Acids, Nucleotides, and Nucleosides
- Nucleosides
- Ribonucleosides
- Ribavirin
- peginterferon alfa-2a
Other Study ID Numbers
Other Study ID Numbers
- 9232-01
- 2000-023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.